Alpha particles are short-ranged high-energy radiations capable of killing in a range of 1 to 3 cells. We are attempting to deliver alpha-emitting isotopes to leukemia cells and small solid tumors using antibodies as ligands.
Many leukemias and some solid cancers are associated with chromosome translocations that result in fusion genes and fusion protein products. The amino acid sequences of these fusion proteins, or mutated sequences, can be used to develop tumor-specific vaccines for treating humans.
We are developing methods and strategies to construct complex molecules with multifunctional capabilities for diagnosis or therapy that might be self-assembling in vivo by use of synthetic nanomaterials and biological ligands.
Actinium-225 is a daughter of thorium-229, which derives from U-233. Actinium can be used to produce Bi-213 in a reusable generator or used alone as an agent for radio-immunotherapy. We are developing methods to attach Ac-225 to proteins for therapeutic use.